Browse CELSR2

Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00002 7 transmembrane receptor (Secretin family)
PF00028 Cadherin domain
PF00008 EGF-like domain
PF16489 GPCR-Autoproteolysis INducing (GAIN) domain
PF01825 GPCR proteolysis site
PF12661 Human growth factor-like EGF
PF00053 Laminin EGF domain
PF02210 Laminin G domain
Function

Receptor that may have an important role in cell/cell signaling during nervous system formation.

> Gene Ontology
 
Biological Process GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0003002 regionalization
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007164 establishment of tissue polarity
GO:0007389 pattern specification process
GO:0009952 anterior/posterior pattern specification
GO:0016055 Wnt signaling pathway
GO:0016358 dendrite development
GO:0021999 neural plate anterior/posterior regionalization
GO:0022407 regulation of cell-cell adhesion
GO:0035567 non-canonical Wnt signaling pathway
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060896 neural plate pattern specification
GO:0060897 neural plate regionalization
GO:0090175 regulation of establishment of planar polarity
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:0198738 cell-cell signaling by wnt
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CELSR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CELSR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CELSR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.1580.0123
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8940.592
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.3610.224
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4480.271
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4470.861
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.450.891
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1070.81
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1440.928
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1190.945
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2040.855
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9970.491
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2470.0971
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CELSR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.111.8-4.71
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113015.4-15.40.482
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CELSR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CELSR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CELSR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CELSR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CELSR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CELSR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCELSR2
Namecadherin, EGF LAG seven-pass G-type receptor 2
Aliases KIAA0279; MEGF3; Flamingo1; CDHF10; ADGRC2; adhesion G protein-coupled receptor C2; EGFL2; cadherin, EGF LAG ......
Chromosomal Location1p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CELSR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.